| Authors: |
Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Lee D; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, United States., Soulos PR; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.; Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, United States., Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Lustberg M; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.; Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT, United States. |
